|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
JANSSEN PHARMACEUTICA N.V.
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
C
|
|
INDICATIONS:
|
|
Conduct disorders in children |
|
Psychosis |
|
Tourette's syndrome |
| |
|
|
SIDE EFFECTS:
|
|
Akathisia |
|
dystonic extrapyramidal effects |
|
parkinsonian extrapyramidal effects |
|
Allergic reaction |
|
anticholinergic effects |
|
CNS effect |
|
decreased thirst, or unusual tiredness or weakness |
|
orthostatic hypotension |
|
persistent tardive dyskinesia |
|
Agranulocytosis |
|
heat stroke |
|
obstructive jaundice |
|
neuroleptic malignant syndrome (NMS) |
|
tardive dystonia |
|
Blurred vision |
|
changes in menstrual period |
|
constipation |
|
dryness of mouth |
|
swelling or soreness in breasts in females |
|
unusual secretion of milk |
|
weight gain |
|
Decreased sexual ability |
|
drowsiness |
|
increased sensitivity of skin to sun |
|
nausea or vomiting |
|
Withdrawal emergent dyskinesia |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
Alcoholism, active |
|
>> Cardiovascular disease, severe, especially angina |
|
>> Epilepsy |
|
Glaucoma or predisposition to |
|
Hepatic function impairment |
|
Hyperthyroidism or thyrotoxicosis |
|
>> Parkinson's disease |
|
Pulmonary insufficiency, such as asthma, emphysema, or acute pulmonary infections |
|
Renal function impairment |
|
>> Sensitivity to haloperidol |
|
>> Urinary retention |
|
|
ADULT DOSE:
|
|
Acute psychosis-Intramuscular, 2 to 5 mg initially, the dosage being repeated at one-hour intervals if necessary, or at four- to eight-hour intervals if symptoms are satisfactorily controlled .
Note: For the rapid control of acute psychosis or delirium, haloperidol has also been administered intravenously, in doses of 0.5 to 50 mg at a rate of 5 mg per minute , the dose being repeated as needed at 30-minute intervals .
Alternatively, the dose of haloperidol can be diluted in 30 to 50 mL of compatible intravenous fluid and administered over 30 minutes . |
|
MAXIMUM ADULT DOSE:
|
|
Intramuscular: 100 mg daily .
|
|
PEDIATRIC DOSE:
|
|
Safety and efficacy have not been established .
|
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
|
|
|
|
|